For individuals living with Transthyretin Amyloid Cardiomyopathy (ATTR-CM), a devastating condition, the arrival of Tafamidis and Tafamidis meglumine represents a true change. These novel therapies protect https://attr-cm219393.designi1.com/62840590/remarkable-attr-cm-breakthrough-the-drug-and-attruby-offer-promise